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Abstract
Galectins, soluble intracellular and extracellular β-galactoside–binding proteins, are known to be involved in the
progression and metastasis of various cancers, including prostate adenocarcinoma, but the detailed mechanism
of their biological roles remains elusive. In the prostate cancer cell lines PC-3 and DU-145, galectin 3 (gal3) is pres-
ent at normal levels, whereas in LNCaP, its expression is silenced. In LNCaP, the gal3 promoter was heavily meth-
ylated, whereas PC-3 or DU-145 cells showed negligible or no methylation in the gal3 promoter indicating a
negative correlation between gal3 promoter methylation and its expression. On immunohistochemical analysis
of normal and tumor prostate tissues, gal3 was found expressed both in nucleus and cytoplasm of benign pros-
tatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and stage I. The expression of the gal3 was found
drastically downregulated in advanced stages and, interestingly, mostly in the cytoplasm. On methylation analysis,
the gal3 promoter in stage II prostate adenocarcinoma (PCa) was found heavily methylated, whereas in stages III
and IV, it was only lightly methylated. However, in stage I PCa, both heavy and light methylations were observed in
the gal3 promoter. In normal and benign prostatic hyperplasia tissues, the gal3 promoter was almost unmeth-
ylated. The differential cytosine methylation in the gal3 promoter in stages I to IV PCa enabled us to develop and
validate a methylation-specific polymerase chain reaction–based sensitive assay specific for stages I and II PCa.
These stages are considered the critical stages for successful intervention, thus underscoring the significance of
this diagnostic assay.
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Introduction
Cell surface proteins such as integrins, osteopontin, and lectins play
important roles in cell-cell and cell–extracellular matrix interactions
and in signal transduction, which, in turn, modulate several biolog-
ical processes including apoptosis, angiogenesis, and cancer metasta-
sis [1–3]. Galectins (gal), a family of β-galactoside–binding proteins,
are involved in growth development as well as cancer progression and
metastasis [4,5]. However, the detailed mechanisms of these func-
tions remain largely unknown. Of the 15 members of the galectin
family identified so far, gal1, gal2, gal5, gal7, gal10, gal11, gal13,
gal14, and gal15 are examples of the “proto” type galectins (one
carbohydrate-recognition domain [CRD] per subunit), whereas gal4,
gal6, gal8, gal9, and gal12 are “tandem-repeat” type galectins, which
contain two CRDs [6]. Gal3 is the only representative of the “chi-
mera” galectin type, containing one CRD connected to a collagen-
like sequence rich in proline and glycine [7]. Galectins may exert
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their multiple biological roles intracellularly within the nucleus or
the cytoplasm, or after their secretion, at the cell surface and/or
the extracellular space, mediating interactions between cells and the
extracellular matrix [2,5,6].
Although most galectins are ubiquitously expressed in various hu-
man tissues, in most cancers, galectins were either upregulated or
downregulated relative to the normal parental tissue [8]. For exam-
ple, gal1 is upregulated in thyroid cancer and uterine sarcoma [9,10],
but its expression is decreased in head and neck cancer relative to the
normal tissue [11]. Similarly, expression of galectin 3 (gal3) is found
upregulated in gastric cancer [12], liver cancer [13], and thyroid
cancer [9], but its expression is downregulated in head and neck can-
cer [11] and uterine sarcoma [10] compared with normal tissues.
In prostate adenocarcinoma (PCa), the expression of gal3 is found
decreased compared with normal prostate tissue [14,15]. In contrast,
the expression patterns of gal8 in prostate tumors are more complex
[16,17]. The expression of some proto type isoforms of gal8, such
as gal8e and gal8g, is increased in the malignant prostate epithelial
cells compared with that in normal and benign cells [18]. However,
some tandem-repeat isoforms of gal8, such as gal8a and gal8b, are
equally expressed in normal, benign, and malignant prostate epithe-
lial cells [18].
Prostate adenocarcinoma is the second most common cancer in
men, and the second leading cause of cancer death (Cancer Facts,
National Cancer Institute; http://cis.nci.nih.gov/fact/5_29.htm).
Hormone therapy is the treatment of choice in men with metastatic
PCa, although eventually most patients relapse to a fatal hormone-
insensitive state. However, if PCa is diagnosed in its early stages such
as stages I and II when the tumor is still confined to the prostate
gland, it can be effectively treated and cured. Combined with the
digital rectal examination, elevated levels of the prostate-specific an-
tigen (PSA) have been widely used to diagnose PCa (Cancer Facts,
National Cancer Institute; http://cis.nci.nih.gov/fact/5_29.htm).
Various conditions such as enlargement or inflammation of the pros-
tate, however, can also lead to elevated levels of PSA. Conversely, PSA
levels may be normal despite the presence of PCa. Thus, PSA screen-
ing for early detection of PCa is not suitable owing to the highly
prevalent false-positive and -negative PSA test results (sensitivity,
90%; specificity, 10%-31%) [19]. Actually, only 25% to 30% of
men who underwent biopsy owing to elevated PSA levels had their
specimens diagnosed with PCa [20]. Most recently, assays based on
the detection of the specific serum marker EPCA-2 (sensitivity, 94%;
specificity, 92%) [21] and overexpression of telomerase (sensitivity,
58%; specificity, 100%) or the DD3 gene (sensitivity, 67%; specific-
ity, 83%) [19] have been established, which bear great promise for
more accurate PCa diagnosis, thus reducing the number of unneces-
sary biopsies.
Epigenetic alterations, including hypermethylation of gene pro-
moters, are also early events in neoplastic progression [22]. Such
alterations are believed to contribute to the neoplastic process by
transcriptional silencing of tumor suppressor gene expression [23].
Thus, methylated genes can serve as biomarkers for early detection
of cancer [24]. In the past years, several qualitative and quantitative
polymerase chain reaction (PCR) methods based on the methylation
of single gene (such as glutathione S -transferase P1 [GSTP1]; spec-
ificity, 79% [25]) or multiple-gene cohort (such as P16/ARF/MGMT/
GSTP1; theoretical sensitivity, 73%; theoretical specificity, 98%
[26]), and recently, a multiplexed urine assay consisting of three
methylation markers, GSTP1, RARB, and APC (sensitivity, 55%;
specificity, 80%) have been developed [27]. However, these detec-
tion methods are yet to be improved in both sensitivity and specific-
ity, and most importantly, they are ineffective for the detection of
early stages of prostate cancer [27,28]. Therefore, a reliable marker
for early detection of PCa is urgently needed.
We have previously demonstrated that in the LNCaP cell line,
the expression of gal3 is negatively regulated by hypermethylation
of its promoter [18]. In this study, we immunohistochemically ana-
lyzed the expression of gal3 in normal and PCa tissues. Gal3 was
detected in both the nucleus and the cytoplasm of normal, benign
prostatic hyperplasia (BPH), high-grade prostatic intraepithelial neo-
plasia (HGPIN), and stage I tissues. However, the expression of gal3
was dramatically decreased in more advanced stages and, interestingly,
mostly in the cytoplasm. Moreover, we have demonstrated heavy
cytosine methylation in the promoter of gal3 in stage II PCa, light
methylation of gal3 promoter in stages III and IV, and both heavy
and light methylations of gal3 promoter in stage I PCa. The gal3 pro-
moter in normal and BPH tissues is almost unmethylated. On the
basis of the methylation results, we developed a methylation-specific
(MS) PCR for the detection of early stages of prostate cancer.
Materials and Methods
Source of Prostate Cancer Cell Lines and Tissues
The human prostate cancer cell lines LNCaP (gal3-negative), PC-3
(gal3-positive), and DU-145 (gal3-positive) were purchased from
American Type Culture Collection (ATCC, Manassas, VA). The tis-
sues from both white and African (aged 48-78 years) were procured
from various sources such as Ambion, National Disease Research In-
terchange (NDRI, Philadelphia, PA), Cooperative Human Tissue
Network (CHTN) of the National Cancer Institute (see Table 1
for pathological details). Each tissue specimen was annotated with
the American Joint Committee on Cancer (AJCC) staging and
TNM classification and Gleason score. Fresh frozen sera from pa-
tients with normal and tumor prostate were obtained from Asterand
(asterand.com) and NDRI.
Cell Culture
LNCaP cells were cultured in phenol red–free RPMI 1640 me-
dium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine
serum (Quality Biologicals, Gaithersburg, MD), 100 units/ml peni-
cillin G sodium, and 100 μg/ml streptomycin sulfate (Sigma). The
cell lines PC-3 and DU-145 were cultured in a mixture of Dulbecco’s
modified Eagle medium and F-12 (1:1 dilution; both from Sigma)
supplemented with 10% fetal bovine serum, penicillin, and strepto-
mycin. All cells were cultured in the presence of 5% CO2 at 37°C.
Expression of Galectins in PCa Cell Lines by Reverse
Transcription–PCR and Western Blot
For RT PCR analysis, total RNA extraction, first strand cDNA
synthesis, and PCR amplification were performed as previously de-
scribed [18]. The nonoverlapping gal1- and gal3-specific primers
were reported earlier [18]. For Western blot, total cell extracts were
subjected to sodium dodecylsulfate–polyacrylamide gel electrophore-
sis (SDS-PAGE) followed by Western blot probed with rabbit poly-
clonal anti-gal3 antibodies [29]. For the development of antibodies,
recombinant gal3 was expressed into Escherichia coli from a construct
made into the pET 30 Ek/Lic vector (Novagen, Madison, WI) and
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purified on a lactosyl-Sepharose column as previously described [29].
Antibodies were raised in rabbits using the purified gal3, affinity-
purified on a Protein A-Sepharose column, and their specificities
were validated as previously described [29]. Preimmune serum was
also subjected to Protein A-Sepharose column to obtain normal IgG.
To construct the gal3 expression plasmid, NdeI and EcoRI restriction
sites were produced by PCR at the 5′- and 3′-end, respectively, of the
gal3 cDNA and the product was ligated into the cohesively NdeI/
EcoRI–digested expression vector pET 30 Ek/Lic vector according to
the manufacturer’s instructions.
Histochemical Analyses of Normal and Tumor Prostate Tissues
Immunohistochemical detection of gal3 using specific anti-gal3
antibody was performed on 5-μm-thick paraffin-embedded sections
containing the most representative tumor areas. In brief, sections were
deparaffinized in xylene, hydrated through graded concentrations of
ethanol and then with distilled water. Samples were heated in a micro-
wave oven in 1× Target Retrieval solution (DAKO, Carpinteria, CA)
and then washed with PBS for 5 minutes. All sections were incubated
in 3% hydrogen peroxide to inhibit endogenous peroxidase. Anti-gal3
antibody (10 μg/ml) was applied to the slides and incubated for
30 minutes at room temperature in a humidified chamber. Protein
A-Sepharose–purified preimmune rabbit serum was used as control.
Sections were incubated with post primary block for 15 minutes
and polymer for 15 minutes (NovoLink Polymer Kit; Novocastra, Vi-
sion BioSystems, Newcastle upon Tyne, United Kingdom). Staining
was visualized with the diaminobenzidine chromogen and counter-
stained with Mayer’s hematoxylin.
Evaluation of Immunohistochemical Staining
Ten high-power field (HPF) (magnification, ×400) of each slide
of tumor has been evaluated by two independent observers (F.C.
and V.R.) to semiquantify the percentage of gal3 immunopositivity
following the protocols previously described [30], and the results
have been used for statistical analyses (analysis of variance, P < .05).
When present in the sections, normal and hypertrophic prostate glands
as well as prostatic intraepithelial neoplasia adjacent to the tumors have
also been evaluated.
Methylation Analyses: Bisulfite Modification of Genomic DNA
Followed by PCR, Cloning, and Sequencing
Genomic DNA from normal, BPH, and tumor tissues were pre-
pared using the NucleoSpin Genomic DNA Extraction Kit (Macherey-
Nagel, Inc., Bethlehem, PA) following the manufacturer’s instructions.
Occasionally, genomic DNA was extracted using DNAEasy kit
(Qiagen, Inc., Valencia, CA) following the manufacturer’s protocol.
Table 1. Pathological Details of Tissue (T) and Serum (S) Specimens and Summary of MS-PCR Results.
Sample T/S Tissue Type AJCC Stage AJCC TNM
Classification




N-1 (T) Normal NA NA NA 66 White NA Ambion 0505-006 − −
N-2 (T) Normal NA NA NA 79 White NA Ambiom 0505-007-1 − −
N-3 (T) Normal NA NA NA 66 White NA Ambion 0505-007-2 − −
N-4 (T) Normal NA NA NA 59 White NA NDRI OD23155 − −
N-5 (T) Normal NA NA NA 73 U NA NDRI OD23791 − +
B-1 (T) BPH NA NA NA 78 U NA NDRI 83-1107 − −
B-2 (T) BPH NA NA NA U U NA NDRI 0056582-01 − −
I-1 (T) Tumor I T1 Nx Mx U 60 U U Collaborat 244850 + −
I-2 (T) Tumor I T1 Nx Mx 3 + 3 = 6 81 U U Collaborat 239521 + −
I-3 (T) Tumor I T1 Nx Mx 3 + 3 = 6 74 U U Collaborat 238708 + +
I-4 (T) Tumor I T1 Nx Mx 3 + 3 = 6 76 U U Collaborat 233011 + +
I-5 (T) Tumor I T1 Nx Mx 2 + 3 = 5 85 U U Collaborat 218496 + +
I-6 (T) Tumor I T1 Nx Mx 4 + 3 = 7 78 U U Collaborat 218163 + +
I-7 (T) Tumor I T1 Nx Mx 3 + 3 = 6 67 U U Collaborat 211841 + +
I-8 (T) Tumor I T1 Nx Mx 4 + 5 = 9 66 U U Collaborat 209668 + +
I-9 (T) Tumor I T1 Nx Mx 3 + 2 = 5 77 U U Collaborat 209667 + +
I-10 (T) Tumor I T1 Nx Mx 3 + 4 = 7 64 U U Collaborat 207087 + +
I-11 (T) Tumor I T1 Nx Mx 3 + 4 = 7 70 U U Collaborat 204782 + +
II-1 (T) Tumor II T2c Nx Mx 3 + 4 = 7 63 African 15% Ambion 0505-023 + +
II-2 (T) Tumor II T2c Nx Mx 3 + 4 = 7 69 White 20% CHTN MAD06-00234 + +
II-3 (T) Tumor II T2c Nx Mx 3 + 3 = 6 48 White 15% CHTN MAD06-00550 + +
II-4 (T) Tumor II T2c Nx Mx 3 + 4 = 7 61 White 10% CHTN MAD07-00014 + +
II-5 (T) Tumor II T2 Nx Mx 3 + 4 = 7 73 U 2.6% NDRI OD23791 + −
II-6 (T) Tumor II T2c Nx Mx 3 + 3 = 6 63 White 10% CHTN MAD06-00581 + +
II-7 (T) Tumor II T2c Nx Mx 3 + 3 = 6 50 African U CHTN MAD06-00504 + +
III-1 (T) Tumor III T3 N0 Mx 3 + 4 = 7 62 White U Ambion 0405-037 − +
III-2 (T) Tumor III T3b N0 Mx 4 + 3 = 7 48 White 90% CHTN MAD03-01617 + +
III-3 (T) Tumor III T3a Nx Mx 3 + 3 = 6 58 White 20% CHTN MAD05-00155 − +
III-4 (T) Tumor III T3a Nx Mx 4 + 3 = 7 66 White 10% CHTN MAD06-00118 − +
III-5 (T) Tumor III T3a Nx Mx 4 + 3 = 7 66 White 25% CHTN MAD06-00536 − +
III-6 (T) Tumor III T3a Nx Mx 3 + 3 = 6 44 White 30% CHTN MAD06-00681 − +
III-7 (T) Tumor III T3 Nx Mx 4 + 3 = 7 45 U U NDRI OD20866 − −
IV-1 (T) Tumor IV T3b N1 Mx 5 + 5 = 10 59 White 80% NDRI OD23155 − +
IV-2 (T) Tumor IV T3b N1 Mx U 66 U U CHTN MAD05-00059 − +
B-1 (S) BPH NA NA NA U U NA NDRI 0056582-02 − −
II-1 (S) Tumor II T2b N0 Mx 4 + 3 = 7 63 White U Asterand 55916A2 + +
II-2 (S) Tumor II T2c N0 Mx 3 + 3 = 6 U White U Asterand 47256A1 + +
III-1 (S) Tumor III T3a N0 Mx 3 + 4 = 7 66 White U Asterand 42629A1 − +
IV-1 (S) Tumor IV T3a N1 Mx 4 + 4 = 8 59 White U Asterand 53962A1 − +
Collaborat indicates collaborator (Dr. Francesco Cappello, University of Palermo, Italy); NA, not applicable; ND, not determined; Negl, negligible; U , unknown.
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To identify cytosine methylation in the gal3 promoter, DNA (500 ng)
from the cell lines or tissues was treated with sodium bisulfite by
EZ Gold Methylation Kit (Zymo Research, Orange, CA) according
to the manufacturer’s instructions and subsequently amplified by
PCR [31] with primer pairs located outside the CpG sites, using
the Multiplex PCR kit (Qiagen, Inc.). This method allows precise
analysis of methylation in a selected region by converting all non-
methylated cytosines (C) into uracil (U) while methylated cytosines
remain unchanged. The primers for gal3 after taking into account
the bisulfite conversion reaction were as follows: (a) forward primer
(HuG3BPF3), 5′-GGAGAGGGTGGGGGATAG-3′ derived from
the wild-type sequence 5′-GGAGAGGGCGGGGGACAG-3′ (rang-
ing from −277 to −260 nt of the promoter sequence [32]); and (b)
reverse primer (HuG3BPR3), 5′-ACACCCTCTCCCCTACCC-3′
derived from the wild-type sequence 5′-GCGCCCTCTCCCTG-
CCC-3′ (ranging from +90 to +107 nt of the promoter sequence).
The PCR product was cloned into a pGEM-T vector (Promega,
Madison, WI) and sequenced [18].
Methylation-Specific and Unmethylation-Specific PCR
The difference between the CD-PCR described in the previous
paragraph and the MS-PCR is the location of primer site. In CD-
PCR, primers are designed based on the regions outside the CpG
islands, and the methylation status of the CpG islands is investigated
by cloning and sequencing of the PCR product. In MS-PCR, the
primers are designed on the CpG sites to enable discrimination be-
tween methylated and unmethylated alleles after bisulfite treatment,
and thus, the methylation status of the CpG islands is assessed directly
from the presence or absence of a PCR product. To identify any
unmethylated DNA allele, PCR was also performed using “unmeth-
ylated” primers. The PCR product obtained with the unmethylated
primers serves also as a positive control for the presence of DNA in
the PCR reaction, which is particularly relevant when methylation-
specific polymerase chain reaction–based sensitive assay (MS-PCR)
with the methylated primers yield a negative result. Taking into ac-
count the bisulfite conversion reaction, the “methylated” primers
were designed as follows: forward primer HuG3BPMF1, 5′-CGT-
TTCGTCGGCGTTCG-3′ (ranging from −9 to +8 of the promoter
sequence [32]); and reverse primer HuG3BPMR1, 5′-CACGC-
AACTCACCGCTCG-3′ (ranging from +47 to +64 of the promoter
sequence). The unmethylated primers, designed by taking into ac-
count the bisulfite conversion reaction, were as follows: forward
primer HuG3BPUF1, 5′-GAGGTTTGGAGTTATTGTTTTG-
TTGGTG-3′ (ranging from −24 to +4 of the promoter sequence);
and reverse primer HuG3BPUR1, 5′-CCCCACACAACTCAC-
CACTCA-3′ (ranging from +47 to +67 of the promoter sequence).
The PCR product is expected only in tubes where methylated prim-
ers interact with the methylated DNA and where unmethylated
primers interact with the unmethylated DNA. The specificities of
the methylated and unmethylated primers were tested using known
methylated and unmethylated DNA under the same PCR condi-
tions. An equal amount of bisulfite-treated DNA (75 ng) was used
for each PCR reaction, and the product was subjected to agarose gel
electrophoresis on a 5% TopVision LE GQ agarose (Fermentas, Glen
Burnie, MD).
For GSTP1 unmethylation-specific PCR and MS-PCR assays, the
unmethylated and methylated primers were designed on the basis of
results previously reported [33], after taking into account the bisulfite
conversion reaction. The primers were as follows: unmethylated for-
ward primer GSTP1UF1, 5′-GGTTAGTTGTGTGGTGATT-
TTGGG-3′ (ranging −196 to −173 nt of the promoter sequence),
unmethylated reverse primer GSTP1UR1, 5′-AACCTCACAA-
CCTCCAAACC-3′ (ranging from −26 to −7); methylated forward
primer GSTP1MF1, 5′-TAGTTGCGCGGCGATTTC-3′ (ranging
from −193 to −176), and methylated reverse primer GSTP1MR1, 5′
AAAACCTCGCGACCTCCG 3′ (ranging from −22 to −5). A second
set of methylated primers (forward GSTP1MF2, 5′-CGGGGTGTA-
GCGGTCGTC-3′ ranging from −141 to −124 nt of the promoter
sequence, and reverse primer GSTP1MR2, 5′-GCCCCAATACT-
AAATCACGAC-3′ ranging from −74 to −53 nt) were designed based
on the study by Cairns et al. [25]. The corresponding unmethylated
primers were as follows: forward GSTP1UF2, 5′-GATGTTTG-
GGGTGTAGTGGTTGTTG-3′ ranging from −147 to −123 nt,
and reverse GSTP1UR2, 5′-CCACCCCAATACTAAATCACAA-
CACC-3′, ranging from −76 to −51 nt of the promoter sequence.
Serum samples from healthy individuals and PCa patients were
subjected to gal3 and GSTP1 MS-PCR as described previously.
For this purpose, genomic DNA from each serum sample was isolated
using the NucleoSpin Genomic DNA extraction kit (Macherey-
Nagel, Inc.) and bisulfite treated using EZ Gold Methylation Kit
as described previously.
Results
Expression of Gal3 in PCa Cell Lines and Prostate
(Normal and Tumor) Tissues
Expression of gal3 in PCa cells was examined by RT-PCR and
Western blot. Gal3 was highly expressed in PC-3 and DU-145 cells,
but negligible or very weak gal3 expression was observed in LNCaP
cells either by RT-PCR (Figure 1A) or by Western blot (Figure 1B).
The gal3 antibodies used in the Western blot were prepared from the
affinity-purified gal3 (purity assessed by SDS-PAGE; Figure 1C ),
and their specificity for gal3 was validated, as the PC-3, but not
LNCaP, and cell extract yielded a band corresponding to 29 kDa
(Figure 1D, upper panel, arrow). Preimmune IgG did not result in
any band (Figure 1D, lower panel ).
We investigated gal3 expression in normal, BPH, and various
stages of PCa (Figure 2). Gal3 was found strongly expressed both
in nucleus and cytoplasm in normal (not shown), BPH (Figure 2A),
and HGPIN, a precursor lesion to development of invasive prostatic
adenocarcinoma (Figure 2B), tissues. Gal3 showed decreasing im-
munopositivity during stage evolution. The data are statistically
significant among groups, except for stages III to IV comparison
(Figure 2G ). Moreover, localization of gal3 is interesting during stage
evolution. In particular, stage I tumors showed a strong immunopos-
itivity in both the nucleus and the cytoplasm (Figure 2C ), whereas
in more advanced stages, immunostaining was less intense and local-
ized mainly in cytoplasm, with rare, occasional nucleus positivity
(Figure 2, D–F ). However, 2 of 10 stage I specimens showed little
or no gal3 immunopositivity (not shown).
Expression of Gal3 in PCa Cell Lines Is Negatively Correlated
with Methylation of Its Promoter
As silencing of the gal3 in LNCaP was shown to be regulated by
methylation of its promoter [18], we analyzed promoter methyla-
tion in the gal3 DNA from PC-3 and DU-145 cells after bisulfite
treatment of DNA followed by CD-PCR using the HuG3BPF3
and HuG3BPR3 primers. No methylation was observed in the pro-
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moter of gal3 DNA from either PC-3 or DU-145 cell lines (Figure 3),
indicating a negative correlation between gal3 promoter methylation
and gal3 expression.
Expression of Gal3 in Normal and Tumor Prostate Tissues Is
Negatively Correlated with Methylation of Its Promoter
To determine whether the differential expression of gal3 in various
stages of tumor is correlated with the cytosine methylation, we exam-
ined the methylation patterns of the gal3 promoter in normal and
tumor tissues after bisulfite treatment of DNA followed by CD-
PCR using the same primers used for the cell line DNA. Results
revealed that the gal3 promoter from multiple stage II tumor speci-
mens is heavily methylated throughout its entire length, but that
from multiple stages III and IV tumor specimens is lightly methyl-
ated. Whereas gal3 promoter in stage III showed few methylation
sites, mostly between −199 and −252 nt, the gal3 promoter from
stage IV tumor specimens was methylated between −112 and −227 nt
(Figure 3). In stage I PCa, however, both light and heavy meth-
ylations are evident in the gal3 promoter. In multiple normal pros-
tate and BPH samples, the gal3 promoter was almost unmethylated
(Figure 3). Overall, results indicated that the decreased expression
of gal3 in tumor prostate is associated with the hypermethylation
of its promoter.
Gal3 MS-PCR Assay for the Detection of Stages I and II
Prostate Tumor
The methylation patterns of the gal3 promoter from the stage I to
IVof PCa led us to design primers specific for stages I and II PCa and
develop the MS-PCR assay (patent pending). Of 34 tissues (5 nor-
mal, 2 BPH, 11 stage I, 7 stage II, 7 stage III, and 2 stage IV) tested,
gal3 MS-PCR identified all stage I and II tumor samples (Figure 4).
The positive PCR reaction was specific as the methylated primers
yielded product only with the methylated DNA control, but not
with the unmethylated DNA control. The gal3 MS-PCR was nega-
tive for normal, BPH, stage III (except one), and stage IV samples.
The PCR with the unmethylated primers were positive in all samples
including stage II indicating the presence of unmethylated gal3
DNA. The product obtained from stage I and II tumor with the
unmethylated primers may not be specific, as unmethylated primers
also yielded product with the control methylated DNA. To identify
the presence of any unmethylated DNA in stage I and II tumor, the
bisulfite-treated DNAs from the stage I and II tumor were subjected
to CD-PCR using the HuG3BPF3 and HuG3BPR3 primers fol-
lowed by cloning and sequencing. Sequencing results revealed not
only fully methylated DNA (Figure 3) but also unmethylated DNA
(not shown). The presence of unmethylated DNA allele in the PCa
specimens may be because the tissue sample is heterogeneous in tu-
mor content.
GSTP1 MS-PCR Assay for the Detection of Later Stages of
Prostate Cancer
Because the gal3 MS-PCR assay described previously reliably iden-
tifies all stages I and II PCa tested, negative results from this assay
may indicate that the test specimen either is normal or contains a
tumor at a stage other than stages I and II. Thus, the gal3 MS-PCR
Figure 1. Expression of gal3 (A, B). Expression of gal3 in PCa cell lines as determined by RT-PCR (A) and Western blot (B). Purification of
human recombinant gal3 (C). 15% SDS-PAGE of the crude extract and the lactosyl-Sepharose–purified gal3 (indicated by single band).
Specificity of anti-gal3 antibodies (D). Crude cell extracts from LNCaP (gal3-negative) and PC-3 (gal3-positive) along with the purified
recombinant gal3 (for positive control) were tested with the purified anti-gal3 antibodies (upper panel) and the purified IgG from pre-
immune serum (lower panel) on Western blot.
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Figure 2. (A–F) Expression of gal3 as determined by immunohistochemical staining using affinity purified specific rabbit anti-gal3 anti-
bodies. Representative immunohistochemistry results. Original magnification, ×400. (A) BPH. (B) HGPIN (aged 76 years). (C) Stage I
(T1 N0 Mx, aged 78 years). (D) Stage II (T2 N0 Mx, aged 67 years). (E) Stage III (T3 N0 Mx, aged 78 years). (F) Stage IV (T4 N0 Mx, aged
76 years). In panels A to C, intense gal3 expression is observed in both the nucleus and the cytoplasm. Insets of panels A to C show gal3
positivity in nuclei. In D, a hypertrophic gland in the middle right, with a very intensive positivity mainly in the cytoplasm, surrounded by
tumoral tissue with a lower positivity mainly in the cytoplasm. (G) Statistical analyses of immunohistochemical results. Analysis of var-
iance showing a significant decrease of gal3 positivity among groups, except when compared with stages III and IV.
Translational Oncology Vol. 2, No. 3, 2009 Galectin 3 Promoter Methylation in Prostate Cancer Ahmed et al. 151
assay is unable to distinguish specimens from individuals with normal
tissue and those patients with stage III or IV PCa (metastatic stage)
tumors. To address this assay limitation, an MS-PCR assay based on
the methylation pattern of the GSTP1 gene was introduced to identify
PCa of stages III and IV. Methylation of GSTP1 correlates positively
with tumor grade and stage (i.e., low methylation in early stages and
high methylation in late stages [34]). Therefore, a method based on
GSTP1 promoter methylation may not be suitable to identify prostate
cancer at early stages, especially at stage II (sensitivity, 50%; specificity,
almost 100%) [26]. Our results revealed that the GSTP1 MS-PCR
detected all stage IV samples (2/2) but only three of seven samples
of stage III (Figure 5). However, the GSTP1 MS-PCR was also pos-
itive for 9 of 11 stage I and for 6 of 7 stage II samples. The GSTP1
MS-PCR was negative for BPH (2/2) and normal samples (except 1 of
5; Figure 5). The inability of GSTP1 MS-PCR to detect all tumor
samples especially higher stage was probably due to the primer loca-
tion, which was based on the promoter methylation results in the
LNCaP cell line [33]. Thus, a second set of methylated primers (for-
ward primer GSTP1MF2 and reverse primer GSTP1MR2) based on
the study by Cairns et al. [25] was designed. The sensitivity of the
GSTP1 MS-PCR with the second set of primers previously discussed
was considerably higher for stage III tumor specimens (6 positive of
7 samples; Figure 5, bottom panel ) compared with the first primer
set. Although further optimization of the GSTP1 MS-PCR assay to
further increase the sensitivity will be required to reach the targeted
assay sensitivity and specificity, the results from the combined MS-
PCR assays for gal3 and GSTP1 clearly identified all but one PCa
sample, including all PCa of early stages.
Gal3 and GSTP1 MS-PCR Assays from Normal and Tumor
Patient Serum Samples
To examine if methylated gal3 and GSTP1 DNA from early stages
of PCa can be detected in biological fluids such as serum and urine,
the bisulfite-treated DNA from the serum samples were subjected to
gal3- and GSTP1-MS-PCR assays. Identification of methylated DNA
in urine would be a critical aspect in the development of noninvasive
diagnostic of early stages of prostate cancer. Serum and urine are
known to have significant amount of soluble circulating small DNA
[34,35]. Moreover, tumor-specific sequences including GSTP1 were
detected in DNA isolated from serum and urine [26,36–39]. Of a
very limited set of serum samples tested, the gal3 MS-PCR assay
was positive for all stage II samples (2/2) and, as expected, negative
for BPH (1/1), stage III (1/1), and stage IV (1/1) samples (Figure 6A).
Further, the GSTP1 MS-PCR assay using the primer pair GSTP1MF1
and GSTP1MR1 identified all tumor serum samples (Figure 6B). Our
results indicate that the combined MS-PCR assay (gal3 and GSTP1)
may represent a powerful tool to reliably identify both early and
advanced PCa, including 100% sensitivity for stage II PCa, which
is considered the critical stage for successful intervention.
Figure 3. Methylation profile of gal3 promoter region (384 bp) from PCa cell lines and normal and tumor prostate tissues. Each row
represents a single cloned allele, and each oval represents a single CpG site (open oval, unmethylated; closed oval, methylated). The
numbering in the schematic diagram at the top represents the position relative to the published transcription site (+1, indicated by the
arrow). For each sample, at least 20 clones were sequenced. Two representative sequences for each of BPH, tumor stage I and stage IV,
and four representative sequences for each of stages II and III were shown.
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Discussion
It has become clear that epigenetic events such as DNA methyla-
tion and histone modification play a crucial role in cancer, including
prostate cancer [40–42]. DNA methylation, catalyzed by DNA
methyltransferases, refers to the covalent bonding of a methyl group
specifically to the dinucleotide CpG. DNA methylation is believed to
alter chromosome structure and define regions for transcriptional
regulation. Clusters of CpG sites (known as CpG islands) are found
in the promoter region of approximately 60% of genes, in exons and
introns, and in repetitive elements [43]. In normal cells, most CpG
islands in the promoter regions are unmethylated whereas CpG is-
lands in intronic regions and repetitive sequences are heavily meth-
ylated, perhaps to help the cell identify regions for gene transcription.
In cancer cells, including prostate cancer, two types of DNA meth-
ylation alterations have been demonstrated. The first is a global hy-
pomethylation, in which the genomes of cancer cells show decreased
methylation compared with normal cells [44]. This hypomethylation
is primarily due to the loss of methylation in repetitive elements and
other nontranscribed regions of the genome, which results in ge-
nomic instability. The second type of methylation alteration in can-
cer cells, known as gene hypermethylation, is the methylation of
CpG islands that lie in promoter regions of tumor suppressor and
other regulatory genes that are normally unmethylated. The pro-
moter regions of these genes are inactivated by methylation, and their
gene expression is silenced [41,42,45,46].
In prostate cancer, a large number of genes such as GSTP1,
MGMT, RASSF1A, APC, and RARβ are hypermethylated [43]. Si-
lencing of these genes is thought to contribute to initiation and pro-
gression of the disease [43]. In this study, we have shown that the
gal3 promoter shows almost complete methylation in all CpG sites
in early stages of prostate cancer, such as stage II, but is lightly meth-
ylated in later stages (III and IV). The gal3 promoter in stage I PCa,
however, showed both light and heavy methylation. The methylation
pattern of the gal3 promoter in the various stages of PCa, and in
particular its complete methylation in early stages, is unique because
in other genes such as GSTP1, CpG methylation correlates positively
with tumor grade and stage (i.e., low methylation in early stages and
high methylation in late stages) [34]. Moreover, heavy methylation of
gal3 throughout the promoter region is distinct only in stages I and II
PCa, but light methylation in the region far away from the transcrip-
tion site is evident in later stages of PCa.
It is unknown if or how gal3 participates in PCa progression and
metastasis by decreasing its expression in early stages and maintain-
ing the low expression in later stages. In normal, BPH, HGPIN, and
most stage I prostate tissues, gal3 is localized in both the nucleus and
the cytoplasm, but interestingly, in the later stages (II, III, and IV)
of PCa, it was mostly found in the cytoplasmic compartment as
evidenced from this study and others [47]. van den Brûle et al.
[47] suggested that the nuclear gal3 might play antitumor activities,
whereas cytoplasmic gal3 could favor tumor progression. This notion
was corroborated from a study where the LNCaP cell line was trans-
fected to generate gal3 expression either in the nucleus or in the cyto-
sol [48]. In that study, nuclear gal3 was shown to suppress tumor,
but cytoplasmic gal3 promoted tumor [48].
The finding that the gal3 promoter is completely methylated in
stages I and II PCa makes the gal3 gene an ideal candidate for
Figure 4. Polymerase chain reaction of bisulfite-treated DNA isolated from normal, BPH, and tumor prostate tissues and unmethylated
control and methylated control plasmid DNA with gal3 unmethylated (U) and methylated (M) primer pairs. The products 92 and 73 bp
obtained from unmethylated and methylated primer pairs, respectively, are shown by arrows. An equal amount of bisulfite-treated DNA
(75 ng) was used for each PCR reaction, and the product was subjected to agarose gel electrophoresis on a 5% TopVision LE GQ agarose.
For unmethylated and methylated controls, 25 ng of plasmid DNA was used.
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Figure 5. Polymerase chain reaction of bisulfite-treated DNA isolated from normal, BPH, and tumor prostate tissues with GSTP1
unmethylated (U) and methylated (M) primer pairs. The products 190 and 189 bp obtained from unmethylated and methylated primer
pairs, respectively, are shown by arrows. Bottom panels: Bisulfite-treated DNA from stages III and IV tumors were also subjected to
PCR with a second pair of unmethylated (expected product size, 97 bp) and methylated (expected product size, 89 bp) primers from
GSTP1 promoter.
Figure 6. Polymerase chain reaction of bisulfite-treated DNA isolated from BPH and tumor serum samples with gal3 (A) and GSTP1 (B)
unmethylated (U) and methylated (M) primer pairs. An equal amount of bisulfite-treated DNA (75 ng) was used for each PCR reaction,
and the product was subjected to agarose gel electrophoresis on either 5% (A) or 3% (B) TopVision LE GQ agarose.
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developing a MS-PCR assay for early diagnosis of PCa. Because in
stages I and II the tumor is still confined to the prostate gland, identi-
fication of these stages is very important for effective intervention and
cure. From previous studies on methylated markers using a single gene
(e.g., GSTP1 [25]) or multiple-gene cohort (e.g., P16/ARF/MGMT/
GSTP1 and GSTP1/RARB/APC), it is known that these markers are
not effective in detecting early stages of prostate cancer [24,27,28].
The assay developed here clearly identified all stages I and II specimens
tested (both tissue and serum), although more specimens should be
tested for achieving a statistically significant data set.
Because the gal3 MS-PCR is designed to target only stages I and II
PCa (negative for normal, BPH, and tumors of higher stages), a com-
plementing assay is required to distinguish all PCa stages from indi-
viduals with normal tissues and patients with BPH. Our results show
that GSTP1 MS-PCR assay is useful in this regard, as methylation of
GSTP1 correlates positively with tumor grade and stage [34]. The
GSTP1 MS-PCR assay described here identified all but one PCa
of higher stages, and thus, optimization to further increase the sen-
sitivity will be required. Overall, the results from the combined MS-
PCR assays for gal3 and GSTP1 clearly identified most PCa samples,
including all stages I and II, which are the critical stages for cancer
prevention and cure.
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